Codexis, Inc. (NASDAQ: CDXS) completes $23.1M common stock sale
Rhea-AI Filing Summary
Codexis, Inc. entered into an Underwriting Agreement with Piper Sandler & Co. and Cantor Fitzgerald & Co. to issue and sell 16,666,667 shares of its common stock in a public offering at $1.50 per share. The underwriters received a 30-day option to purchase up to 2,500,000 additional shares. The transaction was conducted under the company’s effective shelf registration statement on Form S-3 via a prospectus supplement.
The offering closed on July 27, 2026, when Codexis completed the sale and issuance of the 16,666,667 shares and received net proceeds of approximately $23.1 million after underwriting discounts, commissions and estimated expenses. Codexis, along with all directors and executive officers, agreed to a 90-day lock-up on sales or transfers of common stock after July 23, 2026, subject to specified exceptions.
Positive
- None.
Negative
- None.
Filing Explained
At March 31, 2026, Codexis reported
Sources and calculations
- Codexis Form 8-K (2026-07-27)
- Codexis first-quarter 2026 fundamentals (2026-03-31)
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $36,571,000 / ($13,150,000 / 90) = [object Object]
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Shares offered: 16,666,667 shares
Public offering price: $1.50 per share
Underwriters’ option shares: 2,500,000 shares
+4 more
7 metrics
Shares offered
16,666,667 shares
Common stock issued and sold to underwriters in the public offering
Public offering price
$1.50 per share
Price at which the 16,666,667 common shares were offered
Underwriters’ option shares
2,500,000 shares
Maximum additional common shares under 30-day over-allotment option
Net proceeds
$23.1 million
Approximate net proceeds after discounts, commissions and estimated expenses
Option period
30 days
Duration of underwriters’ option to purchase additional shares
Lock-up period
90 days
Period after July 23, 2026 during which company and insiders agreed not to sell stock
Offering close date
July 27, 2026
Date Codexis completed sale and issuance of 16,666,667 shares
Key Terms
Underwriting Agreement, shelf registration statement, prospectus supplement, lock-up, +1 more
5 terms
Underwriting Agreement financial
"entered into an underwriting agreement (the “Underwriting Agreement”) with Piper Sandler"
An underwriting agreement is a contract where a company selling new stocks or bonds hires financial firms to buy those securities and resell them to investors. It matters because the agreement sets the offering price, number of securities, fees and which party bears the risk if sales fall short—think of it as a promise that the sale will happen and a roadmap investors can use to understand how the new securities reach the market.
shelf registration statement regulatory
"effective shelf registration statement on Form S-3 (Registration No. 333-279082)"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
prospectus supplement regulatory
"The Offering was made under a prospectus supplement and accompanying prospectus"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
lock-up financial
"agreed not to sell or transfer any Common Stock held by them for 90 days"
A lock-up is an agreement that prevents company insiders, early investors or employees from selling their shares for a set period after a public share offering. It matters to investors because it temporarily limits the number of shares available to trade—like a scheduled hold on extra inventory—and when that hold ends a large number of shares can enter the market, potentially putting downward pressure on the stock price and revealing insiders’ confidence in the company.
net proceeds financial
"The Company received net proceeds from the Offering of approximately $23.1 million"
The amount of money a company actually keeps from a sale or fundraising after paying all direct costs and fees, similar to take-home pay after taxes and deductions. Investors care because net proceeds determine how much cash is available for things that affect value—paying debt, funding projects, buying assets, or returning money to shareholders—so it influences future growth potential and financial health.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What amount of capital did Codexis (CDXS) raise in its July 2026 stock offering?
Codexis raised approximately $23.1 million in net proceeds from its July 2026 common stock offering. This amount reflects funds received after deducting underwriters’ discounts, commissions, and estimated offering expenses from the sale of 16,666,667 shares.
When did Codexis (CDXS) complete the closing of its common stock offering?
The offering closed on July 27, 2026, when Codexis completed the sale and issuance of the 16,666,667 common shares. Net proceeds of about $23.1 million were generated after underwriting discounts, commissions, and estimated offering expenses.
What lock-up restrictions apply to Codexis (CDXS) and its insiders after the offering?
Codexis and all its directors and executive officers agreed not to sell or transfer common stock for 90 days after July 23, 2026. Any exceptions to this lock-up are described in the prospectus supplement for the offering.
Under what registration statement did Codexis (CDXS) conduct this stock offering?
The common stock offering was conducted under Codexis’ effective shelf registration statement on Form S-3, Registration No. 333-279082. A prospectus supplement and accompanying prospectus governed the terms of the transaction.